title: [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
abstract: CA15-3, a peptide derived from MUC-1, an hormonally-regulated protein, is the most widely used serum marker of breast cancer. CA15-3 level increases at the metastatic phase in 50-80% breast cancer patients. Although rise of CA15-3 precede symptoms of metastasis by a mean time of 2-9 months, current international guidelines do not recommend its routine use for screening for metastases because of moderate sensitivity and absence of clinical impact. We conducted a retrospective study among all patients with metastatic breast cancer seen by three senior breast oncologists during a 4-month period. We evaluated correlation of CA15-3 level at the time of metastatic relapse with ER, PgR and Her2 expressions, tumor type, size and nodal status at initial diagnosis, and sites of metastases. CA15-3 was increased in 168/272 patients (62%) at diagnosis of metastases. ER/PgR positivity was strongly correlated with elevated CA15-3 at this time (P < 0.0001). CA 15-3 was elevated in 69% of the cases of HR+ Her2- primary tumors at time of metastatic relapse. It was elevated in 56% of HR+ Her2+++, 46% of HR- Her2+++ cases and only in 41% of triple-negative cases (P = 0.003). these data confirm that CA 15-3 is very variably elevated at time of metastatic relapse of breast cancer, and this is dependant on HR status.
authors.affiliation: Département de Médecine, Comité de Pathologie Mammaire, Institut Gustave-Roussy, 39 Rue Camille-Desmoulins, 94800 Villejuif, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Bensouda
authors.forename: F
authors.initials: F
authors.lastname: André
authors.forename: T
authors.initials: T
authors.lastname: Boulet
authors.forename: A
authors.initials: A
authors.lastname: Al-Ghuzlan
authors.forename: R
authors.initials: R
authors.lastname: Conforti
authors.forename: F
authors.initials: F
authors.lastname: Troalen
authors.forename: C
authors.initials: C
authors.lastname: Bourgier
authors.forename: H
authors.initials: H
authors.lastname: Errihani
authors.forename: M
authors.initials: M
authors.lastname: Spielmann
authors.forename: S
authors.initials: S
authors.lastname: Delaloge
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood* / Q000737:chemistry / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000097:blood / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000737:chemistry / Q000556:secondary; D018275:Carcinoma, Lobular / Q000097:blood / Q000737:chemistry / Q000556:secondary; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D011987:Receptors, Steroid; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000556:secondary; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D018396:Mucin-1; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D011987:Receptors, Steroid; C539821:NR4A1 protein, human; C508053:ERBB2 protein, human